Company intelligence / Profile preview

Tar81

San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

Tar81 is an early-stage biotechnology company focused on the discovery and development of novel small molecule therapeutics for oncology. The company utilizes a proprietary drug discovery platform to identify and target specific biological pathways involved in cancer progression. While currently operating in stealth or early-development mode, Tar81 aims to address unmet medical needs in the treatment of various solid tumors. The company is part of the growing ecosystem of biotech startups leveraging advanced screening and medicinal chemistry to tackle difficult-to-drug targets.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Tar81.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tar81.

Explore the full profile